



## Turning cancer into a non-lethal disease

### OPPORTUNITY HIGHLIGHTS

<b>Profile/Sector</b>	<ul style="list-style-type: none"><li>Seeking to <b><u>revolutionise the survival of cancer patients using innovative drugs</u></b> designed to stop a cancer switching from a slow-growing, non-lethal disease into a fast-growing, lethal disease</li></ul>
<b>Overview</b>	<ul style="list-style-type: none"><li>Filamon believes that <b><u>successful cancer treatment requires 2 types of anti-cancer drugs</u></b> – those that <b><u>kill cancer cells</u></b> (<i>available</i>) and those that <b><u>block critical support coming from the tumour's micro-environment</u></b> (<i>not available</i>)</li><li>The conversion of cancer into a lethal form is only possible because cancer cells manipulate normal cells in the tumour's immediate environment to support their growth and spread</li><li>Filamon has identified 3 drivers of that manipulation and has <b><u>exclusive rights to 3 drug candidates</u></b> that target each of these 3 drivers, creating an important <b><u>world-first opportunity</u></b><ol style="list-style-type: none"><li>One drug has successfully undergone a Phase 1 trial in cancer patients, with an all-important proof-of-concept Phase 1b/2a trial planned for 2023</li><li>A second drug is a clinic-ready, repurposed drug planned for a proof-of-concept Phase 1b/2a trial in 2023</li><li>The third drug is planned for the clinic in 2024</li></ol></li><li>The 3 Filamon drugs are designed to be <b><u>added to standard anti-cancer treatments</u></b></li><li>Filamon's approach is intended to be used across most types of cancer, but <b><u>initially targeting prostate cancer and melanoma</u></b></li></ul>
<b>Intellectual Property</b>	<ul style="list-style-type: none"><li>The 3 drugs are the subject of <b><u>multiple PCT patent lodgements</u></b></li><li>Each drug derives from a proprietary multi-modal technology platform that has the <b><u>potential for more drugs and more applications beyond cancer</u></b></li></ul>
<b>Investment Type</b>	<ul style="list-style-type: none"><li>Series A (seed) fundraiser</li><li>Ground-floor investment in a clinical-stage company</li></ul>
<b>Transaction Size</b>	<ul style="list-style-type: none"><li>Current round = <b><u>AU\$3M</u></b> (~US\$2.1M)</li><li><b><u>Follow-on rounds</u></b> anticipated through 2024 as Company progresses to having 3 clinical trials underway</li></ul>
<b>Use of Proceeds</b>	<ul style="list-style-type: none"><li>Primarily to <b><u>bring 3 drug candidates into the clinic</u></b></li><li>Continue to build strong patent portfolio and technology know-how</li><li>Cover general business expenses</li></ul>

<b>Shareholding</b>	<ul style="list-style-type: none"> <li>▪ Currently 8 Shareholders, including a large U.S. health services company</li> <li>▪ All ordinary shares in an Australian public (Limited) company</li> </ul>
<b>Commercialization Opportunities</b>	<ul style="list-style-type: none"> <li>▪ Options include a research partnership, out-licensing or sale of individual drug platforms post-Phase 2</li> </ul>
<b>Exit Options</b>	<ul style="list-style-type: none"> <li>▪ Exit options include a listing or sale of Company</li> </ul>
<b>Value drivers</b>	<ul style="list-style-type: none"> <li>▪ Ground-floor entry opportunity to fulfilling a major medical need</li> <li>▪ Highly experienced Board and management with proven track record</li> <li>▪ World-leading position in an important new area of oncology</li> <li>▪ Reduced risk profile due to clinical stage in drug development, including a repurposed drug with an established safety profile</li> <li>▪ All 3 drug candidates delivered orally, significantly reducing manufacturing costs and hospital/patient treatment overheads</li> <li>▪ Pipeline of technology platforms provide extended opportunities for drug development in different therapeutic areas, including chronic inflammatory diseases</li> </ul>

## CONTACT DETAILS:

### Filamon Ltd

**Dr Graham Kelly**  
**Founder & CEO**  
**E: [graham.kelly@filamon.com](mailto:graham.kelly@filamon.com)**  
**M: +61 414 665 213**

**Registered Business Address:**  
**c/- BIO101**  
**Suite 201, 697 Burke Road**  
**Camberwell 3124**  
**Victoria, Australia**  
**[www.filamon.com](http://www.filamon.com)**